Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Regorafenib in Relapsed Glioblastoma. An Observational, Multicentric and Prospective Study. IOV-GB-1-2020 REGOMA-OSS

NCT04810182 is registered in ClinicalTrials.gov with Istituto Oncologico Veneto IRCCS as lead sponsor.

NCT NCT04810182
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04810182 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Regorafenib in Relapsed Glioblastoma. An Observational, Multicentric and Prospective Study. IOV-GB-1-2020 REGOMA-OSS
Lead sponsor
Istituto Oncologico Veneto IRCCS
Phase
Observational
Overall status
Completed
Start date
September 10, 2020
Completion date
December 31, 2023
Enrollment
192 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma multiforme